Yutaka Matsuda received his first Ph.D. from Keio University in 2014. He began his scientific career at Ajinomoto Co. Inc. as a researcher in 2013. He then became an ADC researcher at Ajinomoto Bio-Pharma Services, San Diego, in 2018. In 2021, he received a second Ph.D. degree from the Tokyo University of Pharmacy and Life Sciences. Currently, he is an ADC project manager at Ajinomoto Bio-Pharma Services, San Diego. His research interests include various aspects of ADC technology such as novel conjugation, process development, and analysis. Over the past ten years, he has co-authored more than 30 publications, patents, and book chapters related to medicine, synthetic chemistry, and ADCs. His work has been cited more than 350 times, and his publications have an overall h-index of 13.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.